Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults

Trial Profile

Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Fosfomycin (Primary) ; Piperacillin/tazobactam
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ZEUS
  • Sponsors Zavante Therapeutics
  • Most Recent Events

    • 08 Oct 2017 Outcomes of population pharmacokinetic analysis (refinement) of ZTI-01 using pooled data from healthy subjects (NCT02178254) and patients (NCT02753946) with complicated urinary tract infections, presented at the IDWeek 2017.
    • 08 Oct 2017 Clinical outcome rates by pathogen at the test-of-cure (TOC) visit (Day 19), results presented at the IDWeek 2017
    • 08 Oct 2017 Results presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top